Announcement PDF Transforming Nerve Repair Through Science ReNerve Company presentation Annual General Meeting | October 2026 ASX:RNV ReNerve Company presentation | October 2026 Important Notice & Disclaimer 2 Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation. Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction. Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision. Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. Additional information can be found on the Company’s website (www.renerve.com.au). Speculative nature of investment: Any potential investor should be aware that subscribing for Shares involves various risks. The Shares to be issued pursuant to the Prospectus lodged with ASIC by ReNerve Ltd carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares. An investment in Shares of the Company should therefore be considered very speculative. ReNerve Ltd ABN 23 614 848 216 ReNerve Company presentation | October 2026 ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand. Executive Summary 3 Executive Summary 3 product ranges in the US market with more coming in 2026 to 2029 ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US. Successful ongoing expansion within the first year of ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas. Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons. Development of Novel Nerve Repair & Regeneration Products Expanding Product Portfolio Strong Sales & Distribution Presence Global Expansion & Commercialisation Clinical & Professional Validation Robust R&D pipeline grounded in rigorous science, advancing next-generation nerve repair solutions to deliver better patient outcomes ReNerve Company presentation | October 2026 Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental R&D Product Development Commercial Development On Market Product Company Portfolio 4 ReNerve Company presentation | October 2026 Annual revenue up 88% 5 Quarter highlights Revenue up >50% Compared to the previous qtr 30th of June Cash of $1.48M Signed a $5M funding facility with Riverfort in early July $240,000.00 $220,000.00 $200,000.00 $180,000.00 $160,000.00 $140,000.00 $120,000.00 $100,000.00 $80,000.00 $60,000.00 $40,000.00 $20,000.00 $0.00 ReNerve Quarterly Sales ‘23 to ‘26 Quarter Quarterly Sales (AUD) Commercial Business ReNerve Company presentation | October 2026 Target Market USD$2.0Bn USD$6.0Bn Global Nerve Repair Biomaterial Market USD$1.0Bn 2025 USD$6.19Bn USD$1.90Bn USD$1.10Bn The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. 2031 Our Target Markets Dermal and Amniotic Tissue Surgical Applications (Trauma, plastic surgery) Dermal and Amniotic Tissue Orthopedics (Tendon and Ligament) MarketWide Research – Dermal and Amniotic tissue market report 2025- 2032, Published 2025. 7 Global Nerve Repair Biomaterial Market - $2.0Bn $4.0Bn $6.0Bn $8.0Bn 2024 2025 2026 2027 2028 2029 2030 2031 USD $Bn Global Nerve Repair Biomaterial Market North America Europe 16% 52% 32% Global Market by Segment Nerve Wrap Nerve Conduit Nerve Grafts USD$1.69Bn The Global Nerve Repair Biomaterials Market was valued at USD$1.69Bn in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn.* ~900k Nerve surgeries occur in the United States (US) per annum, with no more than 24% of nerve surgeries restoring to ‘as good as it was’. Nerve Compression Approximately 1-in-4 nerve repair cases receive surgery repair, with 30% failure/revision rates. * Global Nerve Repair Biomaterials Market Research Report (2020 – 2031) Sales and Marketing Update 9 ReNerve Company presentation | October 2026 Focus surgical areas Subspecialties Hand (upper extremity) Breast Lower Extremity (M.D. & DPM) Plastics Reconstruction Head & Neck Spine Robust Portfolio 25distributors In the US 2 direct salespeople Ongoing new approvals All approvals designed to add additional SKUs All call points use all ReNerve products US Market Expanded Distribution Channels ReNerve Company presentation | October 2026 Asia 10 • Significant opportunity • Existing distribution partner in place • Surgeon and hospital engagement already underway India • Strong local partner • Had initial orders and sales last quarter • Now engaging with the local market Hong Kong • Complements rest of Asia strategy • Will focus on key private hospital systems Philippines • Have initiated surgeon engagement • In discussion with local distribution partners • Focus on private hospital systems • Strong initial interest Indonesia • Focus on private hospitals • Looking to partner with local distributors Thailand • Clear target customer group • Have gained initial hospital approvals • Use as a regional distribution hub Malaysia RN-SM-TRN-012 Rev.0 Wound Care Overview and Information Nerve Cuff Key Features ReNerve’s “Align” Clinical Study Definitive clinical study on using NervAlign Nerve Cuff for nerve repair 120 patients per cohort Comparing standard of care vs treatment with NervAlign Nerve Cuff Clinical Use • Hundreds of patients implanted to date • Received positive feedback from surgeons stating it handles well, is pliable and conforms and has resulted in strong patient outcomes. • Positive surgeon feedback when used with attachment methods including sutures, glue, micro clips and ‘nothing’. Product • Bio-absorbed within 6-months. • Produced using a non-toxic method. • Terminally sterilised with no residual chemicals. • Covered under procedural reimbursement rather than individual product reimbursement. • Promotes revascularisation and remodelling • Semi-translucent Patient Benefit ● Requires no change to surgical technique or procedures. ● Available in various sizes with ability to be trimmed to required shape. ● Is pliable and conforms, semi-translucent and easy to use Surgeon Benefit 3 2 1 Patient Results • Protects nerves during recovery post peripheral nerve repair • Great handling characteristics and absorbed within 6 months 12 ReNerve Company presentation | October 2026 The “Align” Study Clinical Study on the NervAlign® Nerve Cuff Undertaking a definitive study in nerve repair following surgical neurolysis to show the benefit of protecting the nerve post nerve repair surgery. Study Design: Two patient cohorts • Control Group: Standard neurectomy repair • Test Group: Neurectomy repair with NervAlign Nerve Cuff • Based on the study which showed clear benefit for using the NervAlign Nerve Cuff Key Outcomes: • Testing for significance in Pain Reduction: ‒ Secondary outcomes in patient recovery ‒ Product performance in surgery • Patient follow up around 6 to 9 months Data presentation • Recruiting the final patients into the study • Data accumulated along the way • Data likely to be published and presented in late 2026/early 2027 Comparison of Patient Pre & Post Surgery Pain Score Standard of Care NervAlign Nerve Cuff Protected The comparison of pain scores between the two cohorts of patients 54% Improvement 95% Improvement 7.1 7.1 3.3 0.4 13 ReNerve Company presentation | October 2026 RN-SM-TRN-012 Rev.0 Wound Care Overview and Information Product Range ReNerve Company presentation | October 2026 15 Empliq Product Portfolio Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Description Single-layer amniotic membrane allograft Double-layer amniotic membrane allograft Placental allograft including amniotic membrane and chorion Deep-layer dermal matrix Clinical Value Natural barrier to protect wounds from external environment Thicker barrier for complex wounds Improved handling characteristics Natural barrier to protect wounds from external environment Additional structural support Natural scaffold for protection, reinforcement and capillary formation No basement membrane - rapid tissue ingrowth and healing Potential Applications DFUs, VLUs, surgical wounds, vulnerable tissue DFUs, VLUs, pressure injury, surgical wounds Breast reconstruction, Tendon augmentation, abdominal wall repair, hernia repair Development Programs Product Development Pipeline Nerve conduit range Nerve Conduit and protector ranges ● Includes the Nerve cap ● Significant scale manufacturing ongoing ● 3 types of conduits to come to market Nerve guide matrix In the commercial development Stage 3 of 4 FDA approval pathway confirmed Next step GMP, commercial manufacturing Strong preclinical data out to 12-month implants 17 ReNerve Company presentation | October 2026 R&D Programs R&D programs | 19 ReNerve Company presentation | October 2026 Exploratory Enhancement of Nerve Growth Collaboration with RMIT with AEA grant funding Partners include: Urologist and Colorectal Surgeon • Evidence suggests PRPs can offer improvements as they contain growth factors eg HGF and IGF-1 and cytokines essential for tissue repair and regeneration. • PRPs can promote SC proliferation, axonal sprouting, remyelination, and alleviate neuropathic pain through modulation of inflammatory pathways and pain signalling mechanisms • Additionally, PRP can promote the production of structural / scaffold molecules, including fibronectin, collagen, and hyaluronic acid. ● PRPs have been widely used “clinically” including as Injections (e.g. in carpal tunnel – offers benefits over steroids) and intraoperatively. ● Consistency in PRP is key - improve via prep. and characterisation Research Context Experimental Approach Potential Regenerative Effects • Isolated Platelet Rich Plasma will be added to nerve cuff (directly or via hydrogel matrix) • PRP Nerve Cuff wrapped around crushed/injured nerve, mimicking damaged to the prostatic nerve plexus (primarily crush, stretch, heat) • Exploring the repair and response to the damaged nerves R&D programs | 20 ReNerve Company presentation | October 2026 Exploratory Enhancement of Nerve Growth Partnership with Vivazome ● Exosomes are membrane-bound vesicles released by cells including stem cells ● Exosomes carry reparative molecules (eg mRNA’s, growth factors) ● Exosomes impact behaviour of other cells, including having anti-fibrotic and anti-inflammatory properties. Research Context Experimental Approach ReNerve has a collaboration with Vivazome to determine whether the addition of specific exosomes to nerve repair scaffolds will improve their efficacy. Vivazome have developed purification processes for consistent exosome production. Method: Load exosomes into cuff/ conduit. Collagen can bind particles, develop loading and release ● Looking for improved and/or accelerated nerve repair and recovery Exosomes Value Drivers for the next 12 to 36 Months ● No expansion of the Empliq range required ● All R&D focused on nerve repair products ● A full portfolio competes with the USD$230M+ revenue a year of AxoGen Building out the product portfolio ● Direct sales the most effective in driving growth ● Direct sales are costly, requiring balance between investment & growth ● Working with distributors to expand market access Building direct sales ● ReNerve focusing on investigator studies to reduce cost but still produce outcomes and data ● Growing data around the benefit of the ReNerve products Build supporting data and sales support Two main drivers: ● Empliq – will drive rapid sales growth ● New products to expand nerve product sales ‘bundle’ Big jumps in sales and revenue 2026 to 2029 all about new products to market and driving sales 21 ReNerve Company presentation | October 2026 ReNerve Company presentation | October 2026 Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental R&D Product Development Commercial Development On Market Product Company Portfolio 2029 – with R&D ongoing 22 Nerve stimulator Nerve PRP program Nerve Exosomes ReNerve Company presentation | October 2026 Executive Summary 23 ReNerve Milestones Continued focus on sales expansion with first direct sales reps now full-time Nerve conduits, nerve guide matrix, nerve caps, nerves stimulators Building a portfolio of offerings into the market to expand revenue streams and able to ‘bundle’ into hospitals Using new markets to expand revenue and support US revenue growth High margin products allows a pathway to a profitable business Contact Us ReNerve Limited info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia +61 (03) 9482 3940 Follow us on socials! ReNerve Company presentation | October 2026